Sclerostin-targeted delivery of PCSK9 siRNA reverses osteoporosis in OVX mice

Area of Science:

• Bone Biology and Metabolism
• Vascular Biology
• Gene Therapy

Background:

• Estrogen deficiency, common in postmenopausal women, leads to bone loss and osteoporosis.
• The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in bone metabolism is an emerging area of research.
• PCSK9 upregulation in ovariectomized (OVX) mice correlates with decreased bone mineral density.

Purpose of the Study:

• To investigate the role of PCSK9 in estrogen deficiency-induced bone loss.
• To develop and evaluate a novel bone-targeted exosome delivery system for PCSK9 inhibition in osteoporosis.

Main Methods:

• Studied PCSK9 levels in OVX mice serum and bone marrow stem cells.
• Utilized PCSK9 genetic knockout mice to assess its effect on bone parameters.
• Engineered bone-targeted exosomes functionalized with an anti-sclerostin fragment for siPCSK9 delivery.
• Evaluated the efficacy of targeted siPCSK9 delivery in OVX osteoporotic mice.

Main Results:

• PCSK9 was significantly upregulated in OVX mice, correlating with reduced bone mineral density.
• PCSK9 knockout ameliorated osteoporosis, improving bone microarchitecture and bone turnover markers.
• The engineered exosome system achieved efficient bone-specific enrichment and siPCSK9 delivery.
• Targeted PCSK9 inhibition in OVX mice markedly attenuated bone loss, increasing bone mass twofold.

Conclusions:

• PCSK9 plays a pivotal role in the pathogenesis of osteoporosis.
• Bone-targeted exosome-mediated siPCSK9 delivery is a viable strategy for treating osteoporosis.
• This approach offers a promising proof-of-concept for exosome-based precision therapy with clinical potential.